EMA/201224/2018

European Medicines Agency decision

P/0143/2018

of 7 May 2018

on the acceptance of a modification of an agreed paediatric investigation plan for peginterferon alfa-2a (Pegasys), (EMEA-000298-PIP01-08-M06) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Contact EMA www.ema.europa.eu/contact

European Medicines Agency decision

P/0143/2018

of 7 May 2018

on the acceptance of a modification of an agreed paediatric investigation plan for peginterferon alfa-2a (Pegasys), (EMEA-000298-PIP01-08-M06) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/94/2010 issued on 2 June 2010, the decision P/169/2011 issued on 8 July 2011, the decision P/274/2011 issued on 4 November 2011, the decision P/0089/2013 issued on 29 April 2013, the decision P/0130/2014 issued on 10 June 2014 and the decision P/0010/2016 issued on 29 January 2016,

Having regard to the application submitted by Roche Registration Ltd on 22 December 2017 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 23 March 2018, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for peginterferon alfa-2a (Pegasys), solution for injection, subcutaneous use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Roche Registration Ltd, 6 Falcon Way, Shire Park, AL7 1TW – Welwyn, Garden City, United Kingdom.

EMA/PDCO/20867/2018
London, 23 March 2018

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-000298-PIP01-08-M06

Scope of the application

Active substance(s):

Peginterferon alfa-2a

Invented name:

Pegasys

Condition(s):

Treatment of chronic hepatitis C

Treatment of chronic hepatitis B

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Solution for injection

Route(s) of administration:

Subcutaneous use

Name/corporate name of the PIP applicant:

Roche Registration Ltd

Information about the authorised medicinal product:

See Annex II

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5510
Send a question via our website www.ema.europa.eu/contact

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Roche Registration Ltd submitted to the European Medicines Agency on 22 December 2017 an application for modification of the agreed paediatric investigation plan with a waiver as set out in the European Medicines Agency's decision P/94/2010 issued on 2 June 2010, the decision P/169/2011 issued on 8 July 2011, the decision P/274/2011 issued on 4 November 2011, the decision P/0089/2013 issued on 29 April 2013, the decision P/0130/2014 issued on 10 June 2014 and the decision P/0010/2016 issued on 29 January 2016.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 23 January 2018.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition

Treatment of chronic hepatitis C

The waiver applies to:

- the paediatric population from birth to less than 3 years of age;
- solution for injection, subcutaneous use;
- on the grounds that clinical studies cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the paediatric population.

1.2. Condition

Treatment of chronic hepatitis B

The waiver applies to:

- the paediatric population from birth to less than 3 years of age;
- solution for injection, subcutaneous use;
- on the grounds that clinical studies cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the paediatric population.

2. Paediatric Investigation Plan

2.1. Condition

Treatment of chronic hepatitis C

2.1.1. Indication(s) targeted by the PIP

Treatment of chronic hepatitis C in combination with other agent(s)

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 3 to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Solution for injection

2.1.4. Measures

Area	Number of studies	Description
Quality-related studies	1	**Study 1** Development of a 90 µg prefilled syringe for subcutaneous use, with six graduations, to indicate doses of 90, 65, 45, 30, 20, and 10 µg
Non-clinical studies	0	Not applicable.
Clinical studies	1	**Study 2** Double-blind (first 24 weeks of treatment), randomised, placebo-controlled trial to evaluate safety and efficacy of ribavirin compared to placebo in children from 5 to less than 18 years of age, treated with peginterferon alfa-2a (NV17424, PEDS-C)
Extrapolation, modelling & simulation studies	1	**Study 3** Extrapolation study on the efficacy of peginterferon alfa-2a in paediatric patients with hepatitis C who 1) have failed previous treatment with interferon alpha (pegylated or non-pegylated) alone or in combination therapy with ribavirin, or 2) have HIV coinfection, or 3) are 3 to less than 5 years of age
Other studies	0	Not applicable.
Other measures	0	Not applicable.

2.2. Condition

Treatment of chronic hepatitis B

2.2.1. Indication(s) targeted by the PIP

Treatment of immune-active phase of chronic hepatitis B

2.2.2. Subset(s) of the paediatric population concerned by the paediatric development

From 3 to less than 18 years of age

2.2.3. Pharmaceutical form(s)

Solution for injection

2.2.4. Measures

Area	Number of studies	Description
Quality-related studies	1	**Study 1** *Same study as for condition "treatment of chronic hepatitis C"*
Non-clinical studies	0	Not applicable.
Clinical studies	1	**Study 4** Open-label, randomised superiority study to compare efficacy and safety of peginterferon alfa-2a monotherapy to an untreated control group in children from 3 to less than 18 years of age with chronic hepatitis B in the immune-active phase (YV25718) *Study 5 was removed as a result of procedure EMEA-000298-PIP01-08-M06.*
Extrapolation, modelling & simulation studies	0	Not applicable.
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By August 2016
Deferral for one or more studies contained in the paediatric investigation plan:	No

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s)

1. Treatment of chronic hepatitis B

Authorised indications:

- Adult patients: Pegasys is indicated for the treatment of hepatitis B envelope antigen (HBeAg)-positive or HBeAg-negative chronic hepatitis B (CHB) in adult patients with compensated liver disease and evidence of viral replication, increased alanine aminotransferase (ALT) and histologically verified liver inflammation and/or fibrosis.
- Paediatric patients 3 years of age and older: Pegasys is indicated for the treatment of HBeAg-positive CHB in non-cirrhotic children and adolescents 3 years of age and older with evidence of viral replication and persistently elevated serum ALT levels.

2. Treatment of chronic hepatitis C

Authorised indications:

- Adult patients: Pegasys is indicated in combination with other medicinal products, for the treatment of chronic hepatitis C (CHC) in patients with compensated liver disease.
- Paediatric patients 5 years of age and older: Pegasys in combination with ribavirin is indicated for the treatment of CHC in treatment-naïve children and adolescents 5 years of age and older who are positive for serum HCV-RNA.
- Authorised pharmaceutical form(s)

Solution for injection

Authorised route(s) of administration

Subcutaneous use